公开(公告)号：US20240181053A1

公开(公告)日：2024-06-06

申请号：US18285135

申请日：2022-03-30

Applicant: NEOGENTC CORP. ,  THE ASAN FOUNDATION ,  University of Ulsan Foundation for Industry Cooperation

Inventor： Hee Jin LEE ,  Kyu Jin LEE ,  Hye Seon PARK ,  Gyung Yub GONG ,  Chae Lyul LIM ,  Young Ae KIM ,  Ji ll CHOI

IPC: A61K39/00 ,  A61P35/00 ,  C12N5/0783

CPC classification number: A61K39/4611 ,  A61P35/00 ,  C12N5/0636 ,  C12N2501/2302 ,  C12N2501/515 ,  C12N2502/11 ,  C12N2506/30

Abstract: A method for producing an immune cell composition is disclosed. The method includes steps of: (a) culturing a tumor sample in a first container, (b) obtaining a first immune cell population from the cultured product obtained from (a); (c) seeding a second composition and a second immune cell population in a second container; (d) expending the second immune cell population to produce a third immune cell population; and (e) obtaining the third immune cell population from the expanded product obtained from (d) and producing the immune cell composition.

公开(公告)号：US20240327861A1

公开(公告)日：2024-10-03

申请号：US18577850

申请日：2022-07-11

Applicant: NEOGENTC CORP.

Inventor： Chae Lyul LIM ,  Young-Ae KIM ,  Jiwon CHUNG ,  Seeun PARK

IPC: C12N15/85 ,  C12N9/12

CPC classification number: C12N15/85 ,  C12N9/1241 ,  C12N2830/50

Abstract: The present invention relates to a transposon vector, a transposon system comprising same, a transposon kit, a cell into which the transposon vector is inserted, and uses thereof, wherein the present invention has been completed by confirming that an exogenous gene is effectively transferred into the chromosome of a target cell to produce a high yield of genetically modified cells. In particularly, it was confirmed that the transposon according to the present invention can effectively transfer a TCR or CAR-encoding gene to immune cells, and cells expressing the TCR or CAR show high reactivity to an antigen, and thus, it is expected that various TCR-T cells and CAR-T cells can be produced by using the transposon system according to the present invention. In particular, CAR-T cells with a high yield can be obtained at a low cost by using the transposon of the present invention, such that the prices of therapeutics can be lowered by lowering the production costs of CAR-T cellular therapeutic agents, whereas conventional CAR-T cells require high costs for the production of CAR as well as transfer to target cells. Moreover, it was confirmed that the transposon of the present invention can effectively transfer an antibody gene, such as an oncovirus-targeting neutralizing antibody, to HEK293 cells used for mass production of antibodies, such that various antibodies can easily be mass-produced by means of the transposon of the present invention In particular, since the transposon according to the present invention is not limited in the type of gene that can be transferred as a vector, it is expected that the transposon can be actively utilized according to various purposes in the development of genome-modified cell lines expressing various genes in addition to antibody genes.